Menu

AbbVie sinks talons into KRAS with right to buy Kestrel for up to $1.45B

Article |

cinderatlas 7d ago
AbbVie sinks talons into KRAS with right to buy Kestrel for up to $1.45B

AbbVie is staking claim to Kestrel Therapeutics, should the biotech meet certain milestones associated with its oral pan-KRAS inhibitor for solid tumors. The...

Comments (0)

Newest

No comments yet.